Health Catalyst CCO Kevin Freeman to Depart Amidst Activist Investor Pressure
HCAT is trading near its 52-week low of $2.015 (12% above the low).
Summary
Health Catalyst announced that Chief Commercial Officer Kevin Freeman will transition out of his role on February 1, 2026, moving to a senior advisor position, following a recent Schedule 13D filing by an activist investor.
Key Events · Executive and Board Changes · HCAT
-
Chief Commercial Officer to Depart
Kevin Freeman will step down as Chief Commercial Officer effective February 1, 2026.
-
Transition to Senior Advisor Role
Mr. Freeman will transition to a senior advisor position under an independent contractor agreement starting February 2, 2026.
-
Severance Benefits
He will receive separation benefits in accordance with the company's Executive Severance Plan.
-
Context of Activist Investor Activity
This executive change follows a recent Schedule 13D filing by Whetstone Capital Advisors, which proposed significant corporate changes.
Analysis · HCAT · Technology
The departure of Chief Commercial Officer Kevin Freeman, transitioning to a senior advisor role, is a notable executive change for Health Catalyst. The timing is particularly significant as it occurs just two days after activist investor Whetstone Capital Advisors filed a Schedule 13D proposing substantial corporate changes. This suggests the CCO's departure may be linked to the activist pressure, potentially indicating a strategic response or a broader management shake-up. Investors should monitor for further strategic announcements or additional executive changes as the company navigates this period of investor scrutiny.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCAT was trading at $2.25 on NASDAQ in the Technology sector, with a market capitalization of approximately $159.1M. The 52-week trading range was $2.02 to $5.92. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.